# Odyssey Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Odyssey Therapeutics, Inc.). ## Overview Odyssey Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing medicines for autoimmune and inflammatory diseases. Its pipeline centers on small-molecule and other precision therapies designed to target disease pathways such as RIPK2 and SLC15A4, with development activities organized around preclinical and clinical programs. ## Products & services • OD-001 oral RIPK2 scaffolding inhibitor • OD-002 small-molecule SLC15A4 inhibitor • Autoimmune and inflammatory disease drug discovery • Clinical development of product candidates • Preclinical research and target validation - **Clinical-stage product candidates** (0%) — Drug candidates in human trials, including OD-001 and other pipeline assets. - **Preclinical discovery programs** (0%) — Research-stage programs aimed at identifying and validating new immune targets. - **Collaboration revenue** (100%) — Revenue from research collaborations, material transfer, option, and license agreements. - OD-001 oral RIPK2 scaffolding inhibitor - OD-002 small-molecule SLC15A4 inhibitor - Autoimmune and inflammatory disease drug discovery - Clinical development of product candidates - Preclinical research and target validation ## Customers Odyssey does not sell approved products today; its near-term counterparties are pharmaceutical collaborators and research partners that support discovery and development programs. If its candidates are approved, the end customers would be physicians, hospitals, patients, and third-party payors in autoimmune and inflammatory disease markets. - **Pharmaceutical collaboration partners** (primary) — Companies that enter research, option, or license agreements to access Odyssey's programs and data. - **Autoimmune disease patients** (primary) — Patients with ulcerative colitis, inflammatory bowel disease, lupus, and related disorders who would use approved therapies. - **Physicians and specialty clinics** (secondary) — Prescribers who would adopt the therapies if clinical data, safety, and convenience support use. - **Third-party payors** (secondary) — Insurers and reimbursement bodies that determine access and utilization for approved medicines. - Pharmaceutical collaborators funding or enabling R&D programs - Research partners under material transfer and license agreements - Physicians treating autoimmune and inflammatory diseases - Hospitals and specialty clinics using approved therapies - Third-party payors evaluating coverage and reimbursement ## Geography Odyssey is headquartered in the United States and conducts its research and development activities from that base. Its business is primarily U.S.-centric today, while collaboration, regulatory, and eventual commercialization exposure could extend to other markets if programs advance. - Headquartered in the United States - R&D and clinical operations are U.S.-based - Collaborations may involve non-U.S. counterparties - Future commercialization could expand beyond the U.S. - Regulatory exposure includes U.S. and foreign authorities ## Strategy Odyssey's strategy is to advance precision medicines for autoimmune and inflammatory diseases, with emphasis on translating target biology into differentiated clinical candidates. It is also building a broader pipeline through discovery, collaboration, and intellectual property development so that multiple programs can progress in parallel. - **Advance OD-001 through clinical development** (short-term) — Clinical proof-of-concept is the key step toward later-stage value creation and eventual approval. - **Broaden the pipeline beyond OD-001** (medium-term) — Multiple programs reduce single-asset dependence and create more shots on goal in immune disease. - **Maintain collaboration and financing capacity** (short-term) — Discovery-stage biopharma requires external capital and partnering to fund long development timelines. - Advance OD-001 into later-stage development - Build combination-trial strategies in inflammatory disease - Progress OD-002 and other pipeline assets - Use collaborations to support discovery and validation - Expand intellectual property around novel immune targets ## Risks Odyssey faces the core risks of clinical-stage biotechnology: uncertain trial outcomes, regulatory approval risk, and the possibility that product candidates never reach commercialization. Its business also depends on capital access, third-party manufacturing, and successful collaboration execution, while autoimmune drug development carries safety, efficacy, reimbursement, and market-adoption risk. - **Clinical development failure** [high] — The company depends on positive efficacy and safety data to move candidates forward. - **Regulatory approval risk** [high] — Even successful trials may not translate into marketing authorization. - **Funding and liquidity dependence** [high] — Research and clinical programs require substantial capital before any product revenue exists. - **Third-party manufacturing reliance** [medium] — Clinical supply depends on CMOs meeting quality, timing, and scale requirements. - **Market acceptance and reimbursement** [medium] — Approved therapies must win physician, patient, and payor adoption to generate revenue. - **Product liability and safety events** [medium] — Unexpected adverse events can create legal exposure and damage adoption. - Clinical trial failure could halt or delay pipeline value creation - Regulatory approval is uncertain for all product candidates - No approved products means no product-sales revenue today - Dependence on third-party CMOs creates supply and quality risk - Future funding needs could force program delays or reductions - Product liability and market-acceptance risk are material if approved ## Accounting The most important accounting judgments are collaboration revenue recognition, accrued research and development costs, stock-based compensation, and fair value measurement of contingent consideration. Because Odyssey is pre-commercial and research-intensive, timing estimates around trial spend, vendor accruals, and partnership milestones can materially affect quarterly results. - **Collaboration revenue recognition** — Can create uneven quarterly revenue - **Accrued research and development costs** — Affects operating expense timing - **Stock-based compensation** — Impacts reported losses and dilution analysis - **Contingent consideration fair value** — Can introduce non-operating volatility - Collaboration revenue depends on contract terms and performance obligations - Accrued R&D costs reflect timing of CRO and CMO invoices - Stock-based compensation is significant for a development-stage biotech - Contingent consideration is marked to fair value each period - Cash runway disclosures depend on management's operating assumptions --- *Last updated: 2026-07-18T04:44:32.144838+00:00*